Current Clinical Needs

  • Giovanni Barosi
Part of the Hematologic Malignancies book series (HEMATOLOGIC)


In the majority of the patients with myeloproliferative neoplasm-associated myelofibrosis (MPN-MF), the disease interferes with the quality of life and social activities. A great proportion of patients suffer of general symptoms, such as fatigue, constitutional symptoms, or pruritus, that reflect the biological activity of the underlying disease. The greatest impact on the patients’ well-being is offered by severe anemia and progressive splenomegaly, and the therapy of these manifestations represents a major medical needs. Some of the disease complications, such as hemorrhagic or thrombotic events and infections, need treatments that are not specific for MPN-MF. On the contrary, treatment of extramedullary nonhepatosplenic hematopoiesis, treatment of pulmonary or portal hypertension, and therapy for the accelerated phase and of blast transformation of the disease are MPN-MF-specific medical needs.


Pulmonary Hypertension Portal Hypertension Iron Overload Transjugular Intrahepatic Portosystemic Shunt National Comprehensive Cancer Network 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Ahlberg K, Ekman T, Gaston-Johansson F et al (2003) Assessment and management of cancer-related fatigue in adults. Lancet 362:640–650PubMedCrossRefGoogle Scholar
  2. Alvarez-Larrán A, Abraldes JG, Cervantes F et al (2005) Portal hypertension secondary to myelofibrosis: a study of three cases. Am J Gastroenterol 100:2355–2358PubMedCrossRefGoogle Scholar
  3. Amitrano L, Guardascione MA, Scaglione M et al (2007) Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 102:2464–2470PubMedCrossRefGoogle Scholar
  4. Barbui T, Barosi G, Birgegard G et al (2010a) Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 29:761–770CrossRefGoogle Scholar
  5. Barbui T, Carobbio A, Cervantes F et al (2010b) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115:778–782PubMedCrossRefGoogle Scholar
  6. Barosi G, Rosti V, Massa M et al (2004) Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 124:618–625PubMedCrossRefGoogle Scholar
  7. Barosi G, Magrini U, Gale RP (2010) Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis? Leuk Res 34:1119–1120PubMedCrossRefGoogle Scholar
  8. Blendis LM, Banks DC, Ramboer C et al (1970) Spleen blood flow and splanchnic haemodynamics in blood dyscrasia and other splenomegalies. Clin Sci 38:73–84PubMedGoogle Scholar
  9. Boutet K, Montani D, Jaïs X et al (2008) Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2:249–265PubMedCrossRefGoogle Scholar
  10. Cervantes F, Alvarez-Larrán A, Arellano-Rodrigo E et al (2006) Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia 20:55–60PubMedCrossRefGoogle Scholar
  11. Cervantes F, Dupriez B, Pereira A et al (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895–2901PubMedCrossRefGoogle Scholar
  12. Cirera I, Elizalde JI, Piqué JM et al (1997) Anemia worsens hyperdynamic circulation of patients with cirrhosis and portal hypertension. Dig Dis Sci 42:1697–1702PubMedCrossRefGoogle Scholar
  13. Coates GG, Eisenberg B, Dail DH (1994) Tc-99 m sulfur colloid demonstration of diffuse pulmonary interstitial extramedullary hematopoiesis in a patient with myelofibrosis. A case report and review of the literature. Clin Nucl Med 19:1079–1084PubMedCrossRefGoogle Scholar
  14. Collado-Hidalgo A, Bower JE, Ganz PA et al (2006) Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 12:2759–2766PubMedCrossRefGoogle Scholar
  15. Cortelezzi A, Gritti G, Del Papa N et al (2008) Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia 22:646–649PubMedCrossRefGoogle Scholar
  16. De Franchis R (2005) Evolving consensus in portal hypertension: report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 43:167–176PubMedCrossRefGoogle Scholar
  17. De Stefano V, Martinelli I (2010) Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 5:487–494PubMedCrossRefGoogle Scholar
  18. Dentali F, Ageno W, Witt D et al (2009) Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. Thromb Haemost 102:501–504PubMedGoogle Scholar
  19. Diehn F, Tefferi A (2001) Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol 115:619–621PubMedCrossRefGoogle Scholar
  20. Dillon SR, Sprecher C, Hammond A et al (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5:752–760PubMedCrossRefGoogle Scholar
  21. Dot JM, Sztrymf B, Yaïci A et al (2007) Pulmonary arterial hypertension due to tumor emboli. Rev Mal Respir 24:359–366PubMedGoogle Scholar
  22. Dubois A, Dauzat M, Pignodel C et al (1993) Portal hypertension in lymphoproliferative and myeloproliferative disorders: hemodynamic and histological correlations. Hepatology 17:246–250PubMedCrossRefGoogle Scholar
  23. Elena C, Passamonti F, Rumi E et al (2011) Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of International Prognostic Scoring System and Dynamic International Prognostic Scoring System. Haematologica 961:167–170CrossRefGoogle Scholar
  24. Elliott MA, Pardanani A, Lasho TL et al (2010) Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica 95:1788–1791PubMedCrossRefGoogle Scholar
  25. Emadi S, Clay D, Desterke C et al (2005) IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood 105:464–473PubMedCrossRefGoogle Scholar
  26. Escartín Marin P, Arenas Mirave JI, Boixeda D et al (1977) Hemodynamic study of the portal system in 6 cases of myeloid metaplasia. Rev Clin Esp 145:271–273PubMedGoogle Scholar
  27. Francia di Celle P, Mariani S, Riera L et al (1996) Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood 87:4382–4389PubMedGoogle Scholar
  28. Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 30:2493–2537PubMedCrossRefGoogle Scholar
  29. Galvao DA, Newton RU (2005) Review of exercise intervention studies in cancer patients. J Clin Oncol 23:899–909PubMedCrossRefGoogle Scholar
  30. Garypidou V, Vakalopoulou S, Dimitriadis D et al (2004) Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. Haematologica 89:245–247PubMedGoogle Scholar
  31. Ghidirim G, Corchmaru I, Mishin I et al (2006) Endoscopic rubber band ligation for bleeding oesophageal varices in portal hypertension due to idiopathic myelofibrosis. J Gastrointestin Liver Dis 15:322PubMedGoogle Scholar
  32. Goh BK, Chen JJ, Tan HK et al (2007) Acute variceal bleed in a patient with idiopathic myelofibrosis successfully treated with endoscopic variceal band ligation. Dig Dis Sci 52:173–175PubMedCrossRefGoogle Scholar
  33. Greaves MW (2007) Recent advances in pathophysiology and current management of itch. Ann Acad Med Singapore 36:788–792PubMedGoogle Scholar
  34. Guglielmelli P, Pancrazzi A, Bergamaschi G et al (2007) Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 137:244–247PubMedCrossRefGoogle Scholar
  35. Halank M, Marx C, Baretton G et al (2004) Severe pulmonary hypertension in chronic idiopathic myelofibrosis. Onkologie 27:472–474PubMedCrossRefGoogle Scholar
  36. Hayes S, Davies PS, Parker T et al (2004) Quality of life changes following peripheral blood stem cell transplantation and participation in a mixed-type, moderate-intensity, exercise program. Bone Marrow Transplant 33:553–558PubMedCrossRefGoogle Scholar
  37. Haznedaroglu IC, Atalar E, Ozturk MA et al (2002) Thrombopoietin inside the pulmonary vessels in patients with and without pulmonary hypertension. Platelets 13:395–399PubMedGoogle Scholar
  38. Hibbin JA, Njoku OS, Matutes E et al (1984) Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 57:495–503PubMedCrossRefGoogle Scholar
  39. Hill G, McClean D, Fraser R et al (1996) Pulmonary hypertension as a consequence of alveolar capillary plugging by malignant megakaryocytes in essential thrombocythaemia. Aust N Z J Med 26:852–853PubMedCrossRefGoogle Scholar
  40. Hou MC, Lin HC, Kuo BI et al (1995) Comparison of endoscopic variceal injection sclerotherapy and ligation for the treatment of esophageal variceal hemorrhage: a prospective randomized trial. Hepatology 21:1517–1522PubMedGoogle Scholar
  41. Hua R, Cao H, Wu ZY (2006) Effects of hemoglobin concentration on hyperdynamic circulation associated with portal hypertension. Hepatobiliary Pancreat Dis Int 5:215–218PubMedGoogle Scholar
  42. Ishii T, Wang J, Zhang W et al (2009) Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 1133:5942–5950Google Scholar
  43. Lee WC, Lin HC, Hou MC et al (1999) Effect of anaemia on haemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 14:370–375PubMedCrossRefGoogle Scholar
  44. Leitch HA, Chase JM, Goodman TA et al (2010) Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol Oncol 28:40–48PubMedGoogle Scholar
  45. Ligumski M, Polliack A, Benbassat J (1978) Nature and incidence of liver involvement in agnogenic myeloid metaplasia. Scand J Haematol 21:81–93PubMedCrossRefGoogle Scholar
  46. Lukie BE, Card RT (1977) Portal hypertension complicating myelofibrosis: reversal following splenectomy. Can Med Assoc J 117:771–772PubMedGoogle Scholar
  47. Marvin KS, Spellberg RD (1993) Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest 103:642–644PubMedCrossRefGoogle Scholar
  48. Menon KV, Shah V, Kamath PS (2004) The Budd-Chiari syndrome. N Engl J Med 350:578–585PubMedCrossRefGoogle Scholar
  49. Mesa RA (2009) How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 113:5394–5400PubMedCrossRefGoogle Scholar
  50. Mesa RA, Li CY, Ketterling RP et al (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105:973–977PubMedCrossRefGoogle Scholar
  51. Mesa RA, Barosi G, Cervantes F et al (2006) Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. Best Pract Res Clin Haematol 19:495–517PubMedCrossRefGoogle Scholar
  52. Mesa RA, Niblack J, Wadleigh M et al (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109:68–76PubMedCrossRefGoogle Scholar
  53. Mesa RA, Green A, Barosi G et al (2011a) MPN-associated myelofibrosis (MPN-MF). Leuk Res 35:12–13PubMedCrossRefGoogle Scholar
  54. Mesa RA, Kantarjian H, Tefferi A et al (2011b) Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. Cancer. doi: 10.1002/cncr.26129
  55. Negaard HF, Iversen N, Bowitz-Lothe IM et al (2009) Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 23:162–169PubMedCrossRefGoogle Scholar
  56. Neville RF, Sidawy AN (1998) Myointimal hyperplasia: basic science and clinical considerations. Semin Vasc Surg 11:142–148PubMedGoogle Scholar
  57. Nikolaidis N, Giouleme O, Sileli M et al (2004) Endoscopic variceal ligation for portal hypertension due to myelofibrosis with myeloid metaplasia. Eur J Haematol 72:379–380PubMedCrossRefGoogle Scholar
  58. Passamonti F, Cervantes F, Vannucchi AM et al (2010a) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 115(9):1703–1708PubMedCrossRefGoogle Scholar
  59. Passamonti F, Rumi E, Elena C et al (2010b) Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. Br J Haematol 150:719–721PubMedCrossRefGoogle Scholar
  60. Perelló A, García-Pagán JC, Gilabert R et al (2002) TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 35:132–139PubMedCrossRefGoogle Scholar
  61. Perros F, Montani D, Dorfmüller P et al (2008) Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 178:81–88PubMedCrossRefGoogle Scholar
  62. Petz LD (1989) Hematologic aspects of liver disease. Curr Opin Gastroenterol 5:372–377CrossRefGoogle Scholar
  63. Pieri L, Bogani C, Guglielmelli P et al (2009) The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica 94:1537–1545PubMedCrossRefGoogle Scholar
  64. Pizcueta P, Piqué JM, Fernández M et al (1992a) Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 103:1909–1915PubMedGoogle Scholar
  65. Pizcueta MP, Piqué JM, Bosch J et al (1992b) Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 105:184–190PubMedGoogle Scholar
  66. Pozner RG, Negrotto S, D’Atri LP et al (2005) Prostacyclin prevents nitric oxide-induced megakaryocyte apoptosis. Br J Pharmacol 145:283–292PubMedCrossRefGoogle Scholar
  67. Rambaldi A, Dellacasa CM, Finazzi G et al (2010) A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 150:446–455PubMedGoogle Scholar
  68. Reisner SA, Rinkevich D, Markiewicz W et al (1992) Cardiac involvement in patients with myeloproliferative disorders. Am J Med 93:498–504PubMedCrossRefGoogle Scholar
  69. Rosenbaum DL, Murphy GW, Swisher SN (1966) Hemodynamic studies of the portal circulation in myeloid metaplasia. Am J Med 41:360–368PubMedCrossRefGoogle Scholar
  70. Rosti V, Bonetti E, Bergamaschi G et al (2010) High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS One 5:e15277PubMedCrossRefGoogle Scholar
  71. Roux D, Merlio JP, Quinton A, Lamouliatte H, Balabaud C, Bioulac-Sage P et al (1987) Agnogenic myeloid metaplasia, portal hypertension, and sinusoidal abnormalities. Gastroenterology 92:1067–1072PubMedGoogle Scholar
  72. Saini KS, Patnaik MM, Tefferi A (2010) Polycythemia vera-associated pruritus and its management. Eur J Clin Invest 40:828–834PubMedCrossRefGoogle Scholar
  73. Shaldon S, Sherlock S (1962) Portal hypertension in the myeloproliferative syndrome and the reticuloses. Am J Med 32:758–764PubMedCrossRefGoogle Scholar
  74. Sikuler E, Kravetz D, Groszmann RJ (1985) Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 248:G618–G625PubMedGoogle Scholar
  75. Silverstein MN, Wollaeger EE, Baggenstoss AH (1973) Gastrointestinal and abdominal manifestations of agnogenic myeloid metaplasia. Arch Intern Med 131:532–537PubMedCrossRefGoogle Scholar
  76. Steensma DP, Hook CC, Stafford SL et al (2002a) Low-dose, single fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 118:813–816PubMedCrossRefGoogle Scholar
  77. Steensma DP, Mesa RA, Li CY et al (2002b) Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 99:2252–2254PubMedCrossRefGoogle Scholar
  78. Sullivan A, Rheinlander H, Weintraub LR (1974) Esophageal varices in agnogenic myeloid metaplasia: disappearance after splenectomy. A case report. Gastroenterology 66:429–432PubMedGoogle Scholar
  79. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haemopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
  80. Takasaki M, Takahashi I, Takamatsu M et al (1996) Endoscopic injection sclerotherapy for esophageal variceal hemorrhage in a patient with idiopathic myelofibrosis. J Gastroenterol 31:260–262PubMedCrossRefGoogle Scholar
  81. Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–1265PubMedCrossRefGoogle Scholar
  82. Tefferi A (2010) Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act. Bone Marrow Transplant 45:419–421PubMedCrossRefGoogle Scholar
  83. Tefferi A, Mesa RA, Pardanani A et al (2009a) Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol 84:265–267PubMedCrossRefGoogle Scholar
  84. Tefferi A, Pardanani A, Lim KH et al (2009b) TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 235:905–911CrossRefGoogle Scholar
  85. Tefferi A, Vaidya R, Caramazza D et al (2011) Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29:1356–1363PubMedCrossRefGoogle Scholar
  86. Tyner JW, Bumm TG, Deininger J et al (2010) CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 115:5232–5240PubMedCrossRefGoogle Scholar
  87. Vannucchi AM, Antonioli E, Guglielmelli P et al (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22(7):1299–1307PubMedCrossRefGoogle Scholar
  88. Vannucchi AM, Guglielmelli P, Lupo L et al. (2010) A phase 1/2 study of RAD001, a mTOR inhibitor, in patients with myelofibrosis: final results. Blood (ASH Annual Meeting Abstracts) 116:314Google Scholar
  89. Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117–1127PubMedCrossRefGoogle Scholar
  90. Wanless IR, Peterson P, Das A et al (1990) Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology 12:1166–1174PubMedCrossRefGoogle Scholar
  91. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735–6741PubMedCrossRefGoogle Scholar
  92. Weinschenker P, Kutner JM, Salvajoli JV et al (2002) Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement. Am J Hematol 69:277–280PubMedCrossRefGoogle Scholar
  93. White SM, Wagner JG, Roth RA (1989) Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats. Toxicol Appl Pharmacol 99:302–313PubMedCrossRefGoogle Scholar
  94. Wiest R, Strauch U, Wagner H et al (2004) A patient with myelofibrosis complicated by refractory ascites and portal hypertension: to tips or not to tips? A case report with discussion of the mechanism of ascites formation. Scand J Gastroenterol 39:389–394PubMedCrossRefGoogle Scholar
  95. Winningham ML, MacVicar MG, Bondoc M et al (1989) Effect of aerobic exercise on body weight and composition in patients with breast cancer on adjuvant chemotherapy. Oncol Nurs Forum 16:683–689PubMedGoogle Scholar
  96. Winningham ML, Nail LM, Burke MB et al (1994) Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum 21:23–36PubMedGoogle Scholar
  97. Wyatt SH, Fishman EK (1994) Diffuse pulmonary extramedullary hematopoiesis in a patient with myelofibrosis: CT findings. J Comput Assist Tomogr 18:815–817PubMedCrossRefGoogle Scholar
  98. Zetterberg E, Popat U, Hasselbalch H et al (2008) Angiogenesis in pulmonary hypertension with myelofibrosis. Haematologica 93:945–946PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Unit of Clinical Epidemiology and Center for the Study of MyelofibrosisIRCCS Policlinico S. Matteo FoundationPaviaItaly

Personalised recommendations